Abstract
Dihydropyrimidinones such as compound 12 exhibited high binding affinity and subtype selectivity for the cloned human alpha(1a) receptor. Systematic modifications of 12 led to identification of highly potent and subtype-selective compounds such as (+)-30 and (+)-103, with high binding affinity (K(i) = 0.2 nM) for alpha(1a) receptor and greater than 1500-fold selectivity over alpha(1b) and alpha(1d) adrenoceptors. The compounds were found to be functional antagonists in human, rat, and dog prostate tissues. Compound (+)-103 exhibited excellent selectively to inhibit intraurethral pressure (IUP) as compared to lowering diastolic blood pressure (DBP) in mongrel dogs (K(b)(DBP)/K(b)(IUP) = 40) suggesting uroselectivity for alpha(1a)-selective compounds.
MeSH terms
-
Adrenergic alpha-1 Receptor Antagonists*
-
Adrenergic alpha-Antagonists / chemical synthesis*
-
Adrenergic alpha-Antagonists / chemistry
-
Adrenergic alpha-Antagonists / metabolism
-
Adrenergic alpha-Antagonists / pharmacology
-
Animals
-
Binding, Competitive
-
Blood Pressure / drug effects
-
Dogs
-
Drug Design
-
Drug Evaluation, Preclinical
-
Humans
-
In Vitro Techniques
-
Male
-
Prostate / metabolism
-
Pyrimidinones / chemical synthesis*
-
Pyrimidinones / chemistry
-
Pyrimidinones / metabolism
-
Pyrimidinones / pharmacology
-
Radioligand Assay
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Adrenergic, alpha-1 / metabolism
-
Stereoisomerism
-
Urethra / drug effects
-
Urethra / physiology
Substances
-
ADRA1A protein, human
-
Adra1a protein, rat
-
Adrenergic alpha-1 Receptor Antagonists
-
Adrenergic alpha-Antagonists
-
Pyrimidinones
-
Receptors, Adrenergic, alpha-1
-
SNAP 6201